ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Icon Public (ICLR), a clinical research organization, surged nearly 11% on Wednesday after delivering first-quarter 2026 results that beat analyst expectations. While revenue grew modestly by 0.9% to $2 billion and net income fell 27%, the company's gross bookings jumped 22% year-over-year to $3.3 billion, signaling strong demand for its services in the biotech and pharmaceutical sectors.

Why Icon Stock Crushed it on Wednesday

The global decentralized clinical trials market is projected to grow from USD 9.9 billion in 2025 to USD 38.3 billion by 2035, at a CAGR of 14.5%. Growth is driven by digital health technologies, remote patient engagement, and ecosystem expansion involving CROs and platform vendors. Oncology represents the largest therapeutic segment at 45% market share, while pharmaceutical and biotech sponsors lead end-user adoption at 55% market share. North America currently dominates, while Asia-Pacific shows the fastest growth.

Global Decentralized Clinical Trials Market Size/Share Worth USD 38.3 Billion by 2035 at a 14.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

ICON PLC (ICLR) Stock Price, Analysis & Trade Signals